



Rx_KnowledgeBase Web App
and dataset Rx_Mappy
by Lend-Rx Technology

Summary

1 | **RX DATA**

Therapeutics, Company Portfolio and Pipeline, Therapeutic by disease/DrugType/Biological Targets, Clinical Trials...

2 | **COVERAGE**

5000+ Companies, 1500 Tickers, 20K+ Therapeutics,

3 | **ACCESS**


WebApp Platform and Historical Point in Time Datasets

4 | **USE CASES**


Competitive Intelligence, Company and Product, Data Enrichment

Biotech
and
Pharma

DATA
COVERAGE



A.I. EXTRACTION, LINKING AND ENRICHMENT OF INFORMATION WITH HUMAN IN THE LOOP



Taxonomies, Ontology and Mapping

THERAPEUTICS TAXONOMY

One permanent Id for each
therapeutics whatever its synonyms
Link to additional identifier: NDC,
Registration Id, Consensus Id

THERAPEUTICS TO COMPANIES MAPPING

Historical Point in time M&A, partnerships...
Clean Company Name
Tickerization

THERAPEUTICS MATURITY MAPPING

Historical Point in time
R&D phases to Approval
By diseases

THERAPEUTICS METADATA

Clean Diseases Names
Biological Targets
Drug types

THERAPEUTICS KPI'S

First in class compound
Supplemental indication
Biological Target validated
...

Datasets Delivery : A weekly or Daily Delivery through S3

4 Drug Metadata

The Drug Metadata dataset below provides dynamic data at the therapeutic level, for a given timestamp of release (RELEASE_DATE) and for each drug (DRUG_ID), we provide : diseases targeted by the therapeutic (TREATMENT_CURRENT_PHASE), phase (TREATMENT_CURRENT_PHASE_END) of the disease trial for the drug. Additional drug metadata such as type of drugs (DRUG_TYPE), drugs biological target (DRUG_TARGET). The file contains also Therapeutics KPIs such as: is the current treatment is an supplemental condition (sNDA) for the Drug (DRUG_ALREADY_APPROVED), is the Drug a First in Class for a disease (DRUG_FIRST_IN_CLASS), and upcoming Catalysts and expected date. Weekly files delivered each Monday (cf. RELEASE_DATE) are FULL REFRESH of Therapeutics data meaning that the file contains all historical data and information updated the previous Friday.

Column Name	Description	Format	Example
DRUG_ID	Unique identifier of the drug	long integer	10759
DRUG_NAMES	Names of the drug. Names of the drug are separated by pipe (not available in trial version)	string, pipe separator	Keytruda
VALUE_DATE	Date of validity of the information (UTC). Information known the previous Friday (D-3) before Data Delivery at Release Day (D)	yyyy-MM-dd	2020-09-21
COMPUTATION_TIME	Date of computation of information. Convention : All information dated at VALUE_DATE are computed the next Monday (same date than delivery) starting at 7:30 UTC	yyyy-MM-dd HH:mm:ss zzz	2020-09-24 07:30:00 UTC
RELEASE_TIME	Timestamp for the moment of data release. For now data is delivered each Monday at 12:00 UTC	yyyy-MM-dd HH:mm:ss zzz	2020-09-24 12:00:00 UTC
RELEASE_DATE	Date of data delivery (UTC). Noon UTC each	yyyy-MM-dd	2020-09-24
DRUG_CURRENT_PHASE	Drug's most advanced clinical stage, phase, nda/bia, approved	string	phase 3
DISEASE_NAME	Name of the disease within Lend-Rx Database. Convention : All disease synonyms from sources are disambiguated with Lend-Rx NLP platform	string	Lung Cancer
DISEASE_ID	Unique identifier for the disease	long integer	460
TREATMENT_PHASE	Drug clinical stage for the disease, phase, nda/bia, approved	string	phase 3
TREATMENT_PHASE_START	VALUE_DATE (referred a last update posted in clinical trial gov for instance) of the effective start (meaning that recruitment started) of the treatment (drug-disease) for the Therapeutic	yyyy-MM-dd	2011-03-11
TREATMENT_PHASE_END	VALUE_DATE (referred to a last update posted in clinical trial gov for instance) at which drug ends treatment (drug-disease) phase. End of treatment phase can be : moving to next development stage (see TREATMENT_PHASE_START) or end phase for termination and expected time for end of trial phase when date is superior to the RELEASE_DATE. For Time Approved, Date is RELEASE_DATE	yyyy-MM-dd	2018-12-31
TARGET_NAMES	Name of the biological targets of the drug. When Therapeutics act on several targets, target name are separated by Pipe separator	string	PD-1
TARGET_ID	Unique identifier for the biological targets of the drug. When Therapeutics act on several targets, target Id are separated by Pipe separator	long integer	1578
DRUG_TYPE	Name of the Drug Type of the drug: ex Monoclonal Antibody, ADC, etc.	string	Monoclonal Antibody
DRUG_TYPE_ID	Unique identifier for the drug type	long integer	15
INACTIVE_TREATMENT	Is the Drug has no treatment ongoing at release date over the last 6 months	Boolean	FALSE
DRUG_ALREADY_APPROVED	Is the Drug already approved for at least one condition at release date	Boolean	TRUE
DRUG_FIRST_IN_CLASS	Is Drug with Disease and Target FIRST IN CLASS, meaning the drug has a novel biological target to address the disease and is the most advanced	Boolean	TRUE
DRUG_TARGET_APPROVED	Is the Target for the Disease has been already approved by regulator	Boolean	TRUE
DRUG_NEXT_CATALYST_TYPE	Next expected catalyst for the Treatment; for example: Primary Completion date, PDUFA	String	PDUFA
DRUG_NEXT_CATALYST_DATE	Expected Date of the next catalyst	yyyy-MM-dd	TRUE
Copyright 2022 Lend-Rx Technology SAS. All right reserved		www.lend-rxtech.com	

- Comprehensive and Quant Friendly Dataset
- Historical Point in Time Data since 2016
- Daily update with from 30 minutes to 24 hours lag
- Historical Data for Trial
- Download [DataDictionary](#)

Web Application DashBoards content

Data vizualization tool, Data download, Report production



COMPETITIVE INTELLIGENCE

Therapeutics by Disease, Drug Targets, Drug Type
Clinical Trials by Disease mapped to Press Releases
Press Releases by Disease, Topics, Date
Catalysts by Disease, Date

COMPANY


Portfolio and Pipeline
Partnerships by Therapeutics
Active Clinical Trials mapped to Press Releases
News classify by Topic and Sentiment
Catalysts

THERAPEUTIC


Conditions by Phase
Therapeutic metadata and KPIs
Historical and Current Clinical Trials
Press Releases with topic and sentiment
Catalysts

Transparency of information

Reach underlying source of information through a simple click



CLICK ON DATA OF INTEREST




TO HAVE MORE DETAIL



AND REACH THE SOURCE OF INFORMATION


Therapeutics Dashboard overview

20K+ Therapeutics, Global coverage



THERAPEUTICS DETAIL

Live and terminated conditions
Therapeutics metadata
Therapeutics Partner



CLINICAL TRIALS


Historical and Current
Access to details and related Press Releases



THERAPEUTIC SALES & EXPECTATIONS

Companies Dashboard overview

5K+ Companies, 1.5K Tickers




FILTERING

Search companies by
Conditions/Technology/Maturity



PORTFOLIO AND PIPELINE

Visualize in graph or tabs
Download data




NEWS&CATALYSTS

News Classified by Topics
Upcoming Company Catalysts


Competitive Intelligence Dashboard overview

1.5K diseases, 1K+ Therapeutic Targets, circa 30 Technologies



THERAPEUTIC COMPETITION

Current and Upcoming
By Timing, By Revenue



CLINICAL TRIALS

Ongoing by Phase
Reach details for Data transparency

Press Releases

Date	Drug	Disease	Topics	Sentiment	Title
2024-06-13	ADBRY	Unknowns / Atopic ...	REGISTRATION_APPROV...	neutral	FDA Approves Adbry® (trilicamab-ldm) Autograft for the Treatment of Adults with Moderate-to-Severe Atopi...
2024-06-10	DAXAS	COPD / Pneumonia / ...	MELESTONE/CONFERENCE	positive	AstraZeneca Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Asthma ...
2024-06-04	orimilast	Atopic Dermatitis	CONFERENCE	positive	UNION Therapeutics announces successful completion of the ADEIOS Phase 2b study and presentation of data at the ...
2024-06-03	stapokibart	Psoriasis / Nails Pol...	CONFERENCE	positive	Keynote Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart fo...
2024-05-21	VTAMA	Atopic Dermatitis / ...	CLINICAL_TRIAL	positive	Dermavant Announces Publication of ADORING 1 & ADORING 2 Pivotal Phase 3 Trials of VTAMA® (upimost) c...
2024-05-21	VTAMA	Atopic Dermatitis / ...	-	neutral	Dermavant Announces Publication of ADORING 1/ADORING 2 Pivotal Phase 3 Trials of VTAMA® (upimost) c...
2024-05-15	APG-777	Atopic Dermatitis	MELESTONE	neutral	Apogen Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Hal...
2024-05-13	APG-777	Atopic Dermatitis	FINANCIAL	neutral	Apogen Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results
2024-05-07	MITCHGA	Psoriasis / Chronic R...	-	neutral	Galderma Receives Filing Acceptances for Mimicimab in Psoriasis Nodularis and Atopic Dermatitis in Four Additio...
2024-05-06	DIG-007	Pharmacology / Alo...	-	neutral	Immagine Reports Positive Interim Results from Phase 2a Trial of DIG-007, a Nondepleting Anti-CD34 Monoclonal ...
2024-05-06	voquelimab	Atopic Dermatitis / ...	FINANCIAL	neutral	Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
2024-05-02	EBGLYSS	Nasal Polyposis / U...	-	neutral	ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zeyss to Investigate the Biology Underl...
2024-04-29	TD4-180955	Atopic Dermatitis	MELESTONE	neutral	Technoderm Medicines Advances TD4-180955 Atopic Dermatitis Clinical Program with Phase 2 Trial

NEWS&CATALYSTS

News Classifier by Topics/Phase/Date
Upcoming Events: Trial Results/Registration
Milestones/Congress



You've heard from us.

we want to hear
from **you.**



+336.5089.9073



contact@lend-rxtech.com



www.lend-rxtech.com